Sugi Predict

Sugi Predict / Compounds / SCHEMBL3937867

SCHEMBL3937867

SCHEMBL3937867

CC(C)N1CCN(C(=O)c2ccc(NC(=O)Nc3ccc(C(F)(F)F)cc3)cc2)CC1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ EPHX2 P34913 14/20 1.00
▸ CNR1 P21554 1/20 0.60
▸ CNR2 P34972 1/20 0.60
▸ TRPV4 Q9HBA0 2/20 0.59
▸ PRKAB2 O43741 1/20 0.56
▸ PRKAG1 P54619 1/20 0.56
▸ PRKAA2 P54646 1/20 0.56
▸ PRKAA1 Q13131 1/20 0.56
▸ PRKAG3 Q9UGI9 1/20 0.56
▸ PRKAG2 Q9UGJ0 1/20 0.56
▸ PRKAB1 Q9Y478 1/20 0.56
▸ SLC6A4 P31645 1/20 0.54
▸ HRH3 Q9Y5N1 1/20 0.54
▸ MEN1 O00255 1/20 0.53
▸ HPGD P15428 1/20 0.53
▸ TSHR P16473 1/20 0.53
▸ KMT2A Q03164 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13503647 0.90 EPHX2 (0.81) EPHX2CNR1CNR2SLC6A4HRH3
SCHEMBL3934244 0.89 EPHX2 (1.00) EPHX2TRPV4HPGD
SCHEMBL3939174 0.86 EPHX2 (1.00) EPHX2CNR1CNR2PRKAB2PRKAG1
SCHEMBL14270955 0.86 EPHX2 (0.76) EPHX2HRH3MEN1KMT2A
SCHEMBL3939233 0.85 EPHX2 (1.00) EPHX2HRH3HPGD
SCHEMBL1177142 0.84 EPHX2 (0.72) EPHX2CNR1CNR2TRPV4PRKAB2
SCHEMBL3939273 0.81 EPHX2 (1.00) EPHX2HPGD
SCHEMBL1431303 0.79 EPHX2 (0.65) EPHX2HRH3MEN1HPGDTSHR
SCHEMBL4004204 0.79 EPHX2 (1.00) EPHX2TRPV4
SCHEMBL19464764 0.78 EPHX2 (0.64) EPHX2HRH3HPGDTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101495119-A Soluble epoxide hydrolase inhibitors ARETE THERAPEUTICS INC (US) 2009-07-29 — — CN claimed
EP-2046329-A2 SOLUBLE EPOXIDE HYDROLASE INHIBITORS Arete Therapeutics, INC. (US) 2009-04-15 — — EP claimed
US-20080032978-A1 SOLUBLE EPOXIDE HYDROLASE INHIBITORS ARETE THERAPEUTICS, INC. 2008-02-07 — — US claimed
WO-2008016884-A2 SOLUBLE EPOXIDE HYDROLASE INHIBITORS ARETE THERAPEUTICS, INC. (US) 2008-02-07 — — WO claimed
CN-101495119-A Soluble epoxide hydrolase inhibitors ARETE THERAPEUTICS INC (US) 2009-07-29 — — CN disclosed
EP-2046329-A2 SOLUBLE EPOXIDE HYDROLASE INHIBITORS Arete Therapeutics, INC. (US) 2009-04-15 — — EP disclosed
WO-2008016884-A2 SOLUBLE EPOXIDE HYDROLASE INHIBITORS ARETE THERAPEUTICS, INC. (US) 2008-02-07 — — WO disclosed
US-20080032978-A1 SOLUBLE EPOXIDE HYDROLASE INHIBITORS ARETE THERAPEUTICS, INC. 2008-02-07 — — US disclosed
US-20080032978-A1 SOLUBLE EPOXIDE HYDROLASE INHIBITORS ARETE THERAPEUTICS, INC. 2008-02-07 — — US disclosed
US-20080032978-A1 SOLUBLE EPOXIDE HYDROLASE INHIBITORS ARETE THERAPEUTICS, INC. 2008-02-07 — — US disclosed
WO-2008016884-A2 SOLUBLE EPOXIDE HYDROLASE INHIBITORS ARETE THERAPEUTICS, INC. (US) 2008-02-07 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080032978-A1 SOLUBLE EPOXIDE HYDROLASE INHIBITORS EPHX1, EPHX2, NCEH1 EPHX2 2/4885CNR1 2165/4885CNR2 1786/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.